Tolerability Comparison of Flarex to Lotemax SM

This study compared the ocular tolerability of fluorometholone acetate ophthalmic suspension 0.1% (FLAREX) to loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) in adult subjects. Each subject received one drop of each product, one in each eye, in a randomized, double-masked design. Comfort, impact on vision, and palpebral conjunctival injection were evaluated at 30 seconds, 5 minutes, and 10 minutes after instillation.

NCT Number	NCT07588074
Lead Sponsor	Harrow Inc Collaborators: Eyevance Pharmaceuticals
Conditions	Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications, Kerato Conjunctivitis Sicca, Dry Eye Syndromes, Postoperative Complications
Enrollment	40 participants
Start Date	2021-05-01
Primary Completion	2021-06-30 (estimated)
Study Completion	2021-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-14